DDD Partners LLC Acquires 999,716 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

DDD Partners LLC boosted its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 202.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,492,992 shares of the company's stock after purchasing an additional 999,716 shares during the quarter. Elanco Animal Health makes up 1.9% of DDD Partners LLC's investment portfolio, making the stock its 25th largest position. DDD Partners LLC owned about 0.30% of Elanco Animal Health worth $15,676,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its position in Elanco Animal Health by 6.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after purchasing an additional 1,074,274 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares during the last quarter. Yousif Capital Management LLC purchased a new position in Elanco Animal Health in the first quarter worth $119,000. Wealth Enhancement Advisory Services LLC bought a new position in Elanco Animal Health in the first quarter valued at $111,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Elanco Animal Health by 9.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 117,611 shares of the company's stock valued at $1,424,000 after acquiring an additional 9,928 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Trading Up 2.4%

ELAN traded up $0.36 on Thursday, hitting $14.87. 2,375,486 shares of the company were exchanged, compared to its average volume of 5,044,934. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.46 and a current ratio of 2.71. The firm has a fifty day simple moving average of $13.71 and a two-hundred day simple moving average of $11.75. The stock has a market capitalization of $7.38 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 2.86 and a beta of 1.67. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $15.78.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the firm posted $0.34 earnings per share. The business's quarterly revenue was down 1.0% compared to the same quarter last year. Sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on ELAN shares. Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Stifel Nicolaus increased their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Finally, Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective for the company in a report on Thursday. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.00.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.